Hikma taps Arestat, a formulation technology for protein- and peptide-based drugs, to develop an injectable medicine, ahead of filing for US FDA approval.
The two companies will combine their digital health services to offer clinical trial participants an inhaler equipped with a sensor to analyze patient adherence.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Mylan and Micro Labs receive US FDA approval for two generic versions of Pfizer and BMS’ Eliquis, marking the first generic approvals of direct oral anticoagulants.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
Amylgen and Neuron-Experts partner to create a comprehensive offering of in-vivo and in-vitro efficacy evaluation for compounds in neurodegenerative diseases.
Catalent completes clinical production of opioid addiction therapeutic developed by Bridge using Zydis technology and gets exclusive license ahead of regulatory filing.
After one year of collaborative work, Metrion and LifeArc agree to continue research on a joint project focused on neuroscience ion channel drug discovery for another year.
Amneal announces acquisition of 65.1% majority interest of generics distributing company, AvKARE, boosting its presence in the generics and federal healthcare market.
Though pharma companies now accept the value of AI and machine learning, extra effort is required by the industry to realize the potential business and patient benefits, says Iqvia exec.
This year brought the ‘biggest momentum shift’ in the adoption of risk-based approach to trial management in the clinical research industry, says CluePoints executive.
